Avanos Medical (AVNS)
(Delayed Data from NYSE)
$21.18 USD
+1.79 (9.23%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $21.18 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value F Growth A Momentum C VGM
Avanos Medical (AVNS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$23.50 | $27.00 | $20.00 | 22.33% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for Avanos Medical comes to $23.50. The forecasts range from a low of $20.00 to a high of $27.00. The average price target represents an increase of 22.33% from the last closing price of $19.21.
Analyst Price Targets (2 )
Broker Rating
Avanos Medical currently has an average brokerage recommendation (ABR) of 2.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 2.67 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, one is Buy, representing 33.33% of all recommendations. A month ago, Buy represented 33.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.67 | 2.67 | 2.67 | 2.67 | 2.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/7/2024 | JMP Securities | David L Turkaly | Hold | Hold |
5/2/2024 | C.L. King & Associates | Kristen M Stewart | Moderate Buy | Moderate Buy |
2/21/2024 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.67 |
ABR (Last week) | 2.67 |
# of Recs in ABR | 3 |
Average Target Price | $23.50 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 153 of 252 |
Current Quarter EPS Est: | 0.29 |